Sign In
Buy BOLD
$2.44
+0.0300 (+1.24%)
At Close: Jul 13, 2026
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
04:07pm, Thursday, 02'nd Jul 2026
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
02:00pm, Thursday, 25'th Jun 2026
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
03:00pm, Tuesday, 23'rd Jun 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
02:11pm, Tuesday, 23'rd Jun 2026
NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is r
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
11:55am, Tuesday, 23'rd Jun 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transacti
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
07:30am, Tuesday, 23'rd Jun 2026
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
07:00am, Friday, 08'th May 2026
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
04:49pm, Friday, 17'th Apr 2026
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findin
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
09:17am, Wednesday, 01'st Apr 2026
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exo
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
03:25am, Friday, 20'th Mar 2026
Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is enterin
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to
NurExone Announces Corporate Updates
08:28am, Wednesday, 11'th Mar 2026
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Award
DOT'S® INTRODUCES DOT'S ORIGINAL SNACK MIX - A BOLD NEW TAKE ON SNACKING
09:00am, Tuesday, 10'th Mar 2026
Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
07:00am, Monday, 09'th Mar 2026
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1
Boundless Bio to Participate in the Leerink Global Healthcare Conference
07:00am, Wednesday, 04'th Mar 2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to
